Sign In
Buy ASMB
$36.33
-0.380 (-1.04%)
At Close: Nov 17, 2025
Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives $41.25 Consensus PT from Brokerages
01:19am, Sunday, 16'th Nov 2025
Assembly Biosciences, Inc. (NASDAQ: ASMB - Get Free Report) has received an average rating of "Moderate Buy" from the seven brokerages that are currently covering the company, MarketBeat Ratings repor
Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates
04:05pm, Monday, 10'th Nov 2025
– Released positive Phase 1b interim results for long-acting helicase-primase inhibitor candidate ABI-5366 showing significant reductions in viral shedding rate and genital lesion rate in recurrent
– Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking poster presentation – SOUTH SAN FRANCISCO, Calif.,
Comparing Amphastar Pharmaceuticals (NASDAQ:AMPH) & Assembly Biosciences (NASDAQ:ASMB)
01:30am, Monday, 20'th Oct 2025
Amphastar Pharmaceuticals (NASDAQ: AMPH - Get Free Report) and Assembly Biosciences (NASDAQ: ASMB - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will
Assembly Biosciences Announces Upcoming Investor Conference Participation
07:00am, Tuesday, 14'th Oct 2025
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, t
– Late-breaking oral presentation highlights interim Phase 1b data reported earlier this year for two cohorts in participants with recurrent genital herpes – – Statistically significant reduct
Assembly Biosciences (ASMB) Surges 9.8%: Is This an Indication of Further Gains?
11:36am, Monday, 22'nd Sep 2025
Assembly Biosciences (ASMB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the n
Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts
04:54pm, Friday, 08'th Aug 2025
Assembly Biosciences, Inc.'s ABI-5366 showed strong interim phase 1b results in HSV-2 recurrent genital herpes patients, with a 94% reduction in HSV-2 shedding and genital lesion rates. Upcoming cat
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
08:05am, Friday, 08'th Aug 2025
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (“Assembly Bio”) (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting seri
– 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo
Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
04:05pm, Wednesday, 06'th Aug 2025
– Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-6250, supporting target daily oral dosing profile and dose-dependent el
Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates
04:05pm, Wednesday, 06'th Aug 2025
– On track for proof-of-concept Phase 1b data no later than this fall in participants with recurrent genital herpes for long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidates,
– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates –
– Study will evaluate safety and antiviral activity of ABI-1179 in participants with recurrent genital herpes – – ABI-1179 IND cleared to support study expansion to sites in United States –
– Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final 400 mg cohort –
